{"title":"The Concept of Personal Utility in Genomic Testing: Three Ethical Tensions.","authors":"Gabriel John Watts, Ainsley J Newson","doi":"10.1080/15265161.2025.2475015","DOIUrl":null,"url":null,"abstract":"<p><p>Health Technology Assessment (HTA) has traditionally focused on efficacy, safety, and cost-effectiveness. There has long been concern, however, that this is determined by the goals of healthcare providers/payers, not patients. As a result, HTA arguably fails to reflect the overall value of health technologies-including their \"non-clinical\" or \"personal\" utility to patients and their families. The use of genomic testing in clinical care is one domain where this problem is evident, as the personal utility of results is often especially significant. As such, there are growing calls for HTA frameworks to adopt personal utility as a distinct element of value when assessing clinical genomic tests. We agree that personal utility is important to HTA in clinical genomics. However, against a trend toward comprehensive conceptions of personal utility within HTA, we advocate for a restrictive approach to assessing the value of personal utility in the case of clinical genomic testing.</p>","PeriodicalId":50962,"journal":{"name":"American Journal of Bioethics","volume":" ","pages":"1-12"},"PeriodicalIF":17.0000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Bioethics","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.1080/15265161.2025.2475015","RegionNum":1,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ETHICS","Score":null,"Total":0}
引用次数: 0
Abstract
Health Technology Assessment (HTA) has traditionally focused on efficacy, safety, and cost-effectiveness. There has long been concern, however, that this is determined by the goals of healthcare providers/payers, not patients. As a result, HTA arguably fails to reflect the overall value of health technologies-including their "non-clinical" or "personal" utility to patients and their families. The use of genomic testing in clinical care is one domain where this problem is evident, as the personal utility of results is often especially significant. As such, there are growing calls for HTA frameworks to adopt personal utility as a distinct element of value when assessing clinical genomic tests. We agree that personal utility is important to HTA in clinical genomics. However, against a trend toward comprehensive conceptions of personal utility within HTA, we advocate for a restrictive approach to assessing the value of personal utility in the case of clinical genomic testing.
期刊介绍：
The American Journal of Bioethics (AJOB) is a renowned global publication focused on bioethics. It tackles pressing ethical challenges in the realm of health sciences.
With a commitment to the original vision of bioethics, AJOB explores the social consequences of advancements in biomedicine. It sparks meaningful discussions that have proved invaluable to a wide range of professionals, including judges, senators, journalists, scholars, and educators.
AJOB covers various areas of interest, such as the ethical implications of clinical research, ensuring access to healthcare services, and the responsible handling of medical records and data.
The journal welcomes contributions in the form of target articles presenting original research, open peer commentaries facilitating a dialogue, book reviews, and responses to open peer commentaries.
By presenting insightful and authoritative content, AJOB continues to shape the field of bioethics and engage diverse stakeholders in crucial conversations about the intersection of medicine, ethics, and society.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
